You are not logged in
You need to be a member to print this page.
Sign up for free membership, or log in.
Find out more about our membership benefits
COX-2 inhibitors: managing comorbidities in primary care
September 2005 Volume 12, Issue 5 Br J Cardiol 2005;12:392-3
Authors:
Rubin Minhas
The recent withdrawal of rofecoxib, a COX-2 inhibitor,
has focussed attention on the use of COX-2
inhibitors and other non-steroidal anti-inflammatory
drugs (NSAIDs) in patients with cardiovascular disease.
In the near future, you will need to be a registered user to view full articles
Already a member? Login now
Comments
There are currently no comments for this article - leave a comment
You must be logged in to post a comment.
Not yet a member? Register now for free.
